About This Fund
UI Investissement Majycc Innovation Santé is a French venture capital fund (FPCI — Fonds Professionnel de Capital Investissement) managed by UI Investissement and dedicated to supporting high-potential French startups in the eHealth, MedTech, and BioTech sectors. Created in 2022 through a collaborative initiative with Majycc eSanté — a digital health platform connecting healthcare industry leaders and technology innovators — the fund brings together a consortium of industrial and institutional co-investors including the SRS Health Group, the Almaviva private clinic group, and the Monceau Holding, creating a strategic ecosystem that provides portfolio companies with both capital and direct pathways into healthcare operations networks across France.
The fund intervenes at the late venture stage, specializing in Series A and Series B financing rounds in companies developing innovations across digital health and connected medical devices, medical technology and diagnostic platforms, and biopharmaceutical R&D in France and across Europe. Its investment thesis is grounded in the conviction that technology-driven healthcare innovation — ranging from AI-powered diagnostic software and e-health interoperability platforms to novel drug delivery mechanisms and genomic therapeutics — offers compelling risk-adjusted returns when backed by strategic industrial co-investors with operational realities throughout the healthcare value chain. UI Investissement brings more than 50 years of experience developing French unlisted SMEs and mid-cap businesses to the fund's day-to-day investment management across its healthcare vertical.
UI Investissement is one of France's leading independent private equity and venture capital managers, with approximately €1.5 billion under management across its three core investment verticals of healthcare, agro-business, and business services. The Majycc Innovation Santé fund reached its first closing at over €50 million in late 2022 and has since built an active portfolio of investments including Lifen (healthcare data interoperability), Gleamer (AI-powered radiology), and Naox, demonstrating the fund's ability to identify and back scalable technology-enabled healthcare businesses at the intersection of clinical need and digital innovation across the French and European markets.